Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (181-190 of 323) with videos related to

Pageof 33
Sort By:
Human Pathology|July 27, 2021
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasiaAnne Offermann, Vincent Joerg, Marie C Hupe, et al.
Aktuelle Urologie|June 1, 2021
[Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance]Marie Christine Hupe, Marten Müller, Julian Peter Struck, et al.
Aktuelle Urologie|September 24, 2020
[CARD study: relevance for the treatment of advanced prostate cancer]Axel S Merseburger, Andreas Bannowsky, Klaus Becker, et al.
Urologia Internationalis|March 7, 2018
Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current PracticeSerkan Dogan, Martin Hennig, Tanja Frank, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 9, 2016
(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapyChristoph Henkenberens, Christoph A von Klot, Tobias L Ross, et al.
World Journal of Urology|July 16, 2022
Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancerMaria Frantzi, Isabel Heidegger, Marie C Roesch, et al.
Seminars in Oncology|November 9, 2021
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trialsEkaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, et al.
BJU International|April 16, 2008
Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancerDavid Schilling, Heinz P Schlemmer, Philipp H Wagner, et al.
European Urology Oncology|September 1, 2024
Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center AnalysisMike Wenzel, Cristiana Cano Garcia, Clara Humke, et al.
BJU International|April 24, 2024
Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysisReza Sari Motlagh, Alireza Ghoreifi, Takafumi Yanagisawa, et al.
Pageof 33

Showing results (181-190 of 323) with videos related to

Sort By:
Pageof 33
Human Pathology|July 27, 2021
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasiaAnne Offermann, Vincent Joerg, Marie C Hupe, et al.
Aktuelle Urologie|June 1, 2021
[Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance]Marie Christine Hupe, Marten Müller, Julian Peter Struck, et al.
Aktuelle Urologie|September 24, 2020
[CARD study: relevance for the treatment of advanced prostate cancer]Axel S Merseburger, Andreas Bannowsky, Klaus Becker, et al.
Urologia Internationalis|March 7, 2018
Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current PracticeSerkan Dogan, Martin Hennig, Tanja Frank, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 9, 2016
(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapyChristoph Henkenberens, Christoph A von Klot, Tobias L Ross, et al.
World Journal of Urology|July 16, 2022
Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancerMaria Frantzi, Isabel Heidegger, Marie C Roesch, et al.
Seminars in Oncology|November 9, 2021
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trialsEkaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, et al.
BJU International|April 16, 2008
Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancerDavid Schilling, Heinz P Schlemmer, Philipp H Wagner, et al.
European Urology Oncology|September 1, 2024
Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center AnalysisMike Wenzel, Cristiana Cano Garcia, Clara Humke, et al.
BJU International|April 24, 2024
Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysisReza Sari Motlagh, Alireza Ghoreifi, Takafumi Yanagisawa, et al.
Pageof 33